Elutia Inc. Total Liabilities
Elutia Inc. total liabilities. Based on the latest financial reports, Elutia Inc. (ELUT) has total liabilities worth $27.90 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Elutia Inc. (ELUT) liquidity interval to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Elutia Inc. (2018–2025)
Total liabilities of Elutia Inc. from 2018 to 2025. This chart illustrates how Elutia Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Elutia Inc. Competitors by Total Liabilities
The table below lists competitors of Elutia Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Buima Group
TWO:5543
|
Taiwan | NT$1.90 Billion |
|
Katapult Holdings Inc
NASDAQ:KPLT
|
USA | $110.12 Million |
|
biote Corp
NASDAQ:BTMD
|
USA | $136.99 Million |
|
Harn Engineering Solutions Public Company Limited
BK:HARN
|
Thailand | ฿450.08 Million |
|
JCH Systems Inc
KQ:033320
|
Korea | ₩42.00 Billion |
|
GP Petroleums Limited
NSE:GULFPETRO
|
India | Rs591.82 Million |
|
Salter Brothers Emerging Companies Ltd
AU:SB2
|
Australia | AU$1.98 Million |
|
AGRONOMICS LTD.LS-0000001
F:V77
|
Germany | €234.67K |
Liability Composition Analysis (2018–2025)
This chart breaks down Elutia Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Elutia Inc. asset portfolio.
Liquidity & Leverage Metrics
Elutia Inc. Total Liabilities Ratios Explained
Elutia Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.77 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Elutia Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Elutia Inc. (2018–2025)
The table below shows the annual total liabilities of Elutia Inc. from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $34.68 Million | -57.91% |
| 2024-12-31 | $82.39 Million | +0.44% |
| 2023-12-31 | $82.03 Million | +11.04% |
| 2022-12-31 | $73.87 Million | +37.70% |
| 2021-12-31 | $53.65 Million | -13.44% |
| 2020-12-31 | $61.98 Million | -37.95% |
| 2019-12-31 | $99.88 Million | +9.58% |
| 2018-12-31 | $91.15 Million | -- |
About Elutia Inc.
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDer… Read more